Stroke, systemic embolism, and major bleeding in patients with venous thromboembolism during Vitamin K antagonist treatment. Results from the EVENT HO study
Revista Sangre · 2022
DOI: 10.24875/sangre.21000003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Sangre, 2022. Verfasst von Olga Gavín-Sebastián und 5 weiteren Autor:innen.
Themen: Thromboseprophylaxe, Schlaganfall
Abstract (Originalsprache)
venous thromboembolism during vitamin K antagonist treatment. Results from the EVENTHO study
Zitieren
APA
Gavín-Sebastián, O., Roldán, V., Llamas-Sillero, P., Santamaría, A., Arumí, D., & Fernández-de-Cabo, S. (2022). Stroke, systemic embolism, and major bleeding in patients with venous thromboembolism during Vitamin K antagonist treatment. Results from the EVENT HO study. Revista Sangre. https://doi.org/10.24875/sangre.21000003
Vancouver
Gavín-Sebastián O, Roldán V, Llamas-Sillero P, Santamaría A, Arumí D, Fernández-de-Cabo S. Stroke, systemic embolism, and major bleeding in patients with venous thromboembolism during Vitamin K antagonist treatment. Results from the EVENT HO study. Revista Sangre. 2022. doi:10.24875/sangre.21000003
BibTeX
@article{GavnSebastin2022,
author = {Gavín-Sebastián, Olga and Roldán, Vanessa and Llamas-Sillero, Pilar and Santamaría, Amparo and Arumí, Daniel and Fernández-de-Cabo, Susana},
title = {Stroke, systemic embolism, and major bleeding in patients with venous thromboembolism during Vitamin K antagonist treatment. Results from the EVENT HO study},
journal = {Revista Sangre},
year = {2022},
doi = {10.24875/sangre.21000003}
}
EUVIMED